PETER G. TRABER, M.D.; DONALD P. LEVINE, M.D.
Despite its apparent efficacy against gram-positive organisms, vancomycin has been relegated to second-choice status, largely because of reports of auditory and nephrotoxicity. The increased purity of today's preparations has virtually elemented the risk of nephrotoxicity (1). Ototoxicity, however, is still considered a threat in patients with impaired renal function, despite the fact that all the evidence comes from reports of patients who received other ototoxic drugs or who had pre-existing deafness (1-3). We review the relevant literature and report a case of ototoxicity in a patient with normal renal function who was treated with vancomycin and rifampin but no other
TRABER PG, LEVINE DP. Vancomycin Ototoxicity in a Patient with Normal Renal Function. Ann Intern Med. ;95:458–460. doi: 10.7326/0003-4819-95-4-458
Download citation file:
Published: Ann Intern Med. 1981;95(4):458-460.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use